Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
H Tao, Q Meng, M Li, L Shi, J Tang, Z Liu - Thoracic Cancer, 2018 - Wiley Online Library
Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
H Tao, Q Meng, M Li, L Shi, J Tang, Z Liu - Thoracic Cancer, 2018 - europepmc.org
BACKGROUND: VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
[HTML][HTML] Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
H Tao, Q Meng, M Li, L Shi, J Tang, Z Liu - Thoracic Cancer, 2018 - ncbi.nlm.nih.gov
Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion
H Tao, Q Meng, M Li, L Shi, J Tang… - Thoracic cancer, 2018 - pubmed.ncbi.nlm.nih.gov
Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
T Hong, Q Meng, M Li, L Shi, J Tang, Z Liu - Thoracic Cancer, 2018 - search.proquest.com
Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
H Tao, Q Meng, M Li, L Shi, J Tang, Z Liu - Thoracic Cancer, 2018 - europepmc.org
BACKGROUND: VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …